AstraZeneca/BMS plan European launch for Onglyza by year-end
This article was originally published in Scrip
Executive Summary
The European Commission has granted marketing authorisation to AstraZeneca/Bristol-Myers Squibb's Onglyza (saxagliptin) for type II diabetes as an add-on therapy.